Levemir (insulin detemir rDNA origin) / Novo Nordisk - LARVOL DELTA

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=85 | Terminated | Sponsor: Emory University | N=255 ➔ 85 | Active, not recruiting ➔ Terminated; The study was suspended and during this time recruitment and study activities were halted. The study was ultimately terminated in April 2026 without having re-opened for recruitment additional participants.

Enrollment change • Trial termination • Diabetes • Metabolic Disorders

Initial treatment for uncontrolled type 2 diabetes: A clinical trial comparing basal insulin and modified-release gliclazide. (PubMed, Caspian J Intern Med) - "The patients were randomly assigned into one of two intervention groups: the Gliclazide-MR group (n=45), receiving 30 mg of modified-release gliclazide twice daily, or the Basal Insulin group (n=45), receiving basal insulin (detemir or glargine) at a dosage of 0.1--0.3 units per kilogram of body weight. Both basal insulin and modified-release gliclazide demonstrated efficacy in improving glycemic control in patients with severe hyperglycemia. The optimal treatment choice should be individualized based on patient-specific factors and treatment goals."

Journal • Diabetes • Endocrine Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Alström syndrome in a Chinese girl: a case report and literature review. (PubMed, Transl Pediatr) - "For glycemic control, the patient was managed with a combination of insulin aspart, insulin detemir, and metformin. The clinical presentation highlights the remarkable phenotypic variability of the disorder, a key factor contributing to frequent diagnostic delays or errors. Consequently, early genetic confirmation is imperative to guide appropriate and timely interventions that can significantly improve patient care and quality of life."

Journal • Alstrom Syndrome • Diabetes • Genetic Disorders • Metabolic Disorders • Ophthalmology • Otorhinolaryngology

Insulin Desensitization and Omalizumab Use during Pregnancy in A Patient with Diabetes Mellitus and Severe Insulin Allergy (ENDO 2026) - "In prior pregnancies, she required high-dose insulin (detemir 120 U twice daily and lispro 50–60 U three times daily)...Despite partial tolerance, pregnancy glycemic goals remained unmet on insulin degludec, metformin, and glyburide with CGM data showing fasting hypoglycemia and postprandial hyperglycemia...She delivered via scheduled cesarean section at 36 weeks for fetal macrosomia...The use of omalizumab can serve as an adjunct to reduce IgE-mediated hypersensitivity and facilitate safe insulin desensitization in a highly sensitized patient. This case underscores the value of multidisciplinary care, individualized desensitization strategies, and vigilant maternal-fetal monitoring to optimize outcomes."

Clinical • Allergy • Diabetes • Endocrine Disorders • Hypoglycemia • Immunology • Metabolic Disorders • Pruritus

Insulin NPH-Induced Pityriasis Rubra Pilaris: A Rare Cutaneous Adverse Event (ENDO 2026) - "Given the close temporal relationship with insulin initiation and symptom onset, NPH insulin was discontinued and replaced with insulin detemir, achieving adequate glycemic control. The patient was treated with high dose oral isotretinoin and topical clobetasol... This case highlights a rare but potentially severe cutaneous adverse reaction associated with NPH insulin. Awareness of uncommon dermatologic manifestations of insulin therapy is essential, as early recognition and prompt modification of treatment can lead to favorable outcomes without compromising glycemic control."

Adverse events • Diabetes • Lipodystrophy • Metabolic Disorders • Pruritus

Impact of Glucagon-Like Peptide-1 Receptor Agonists on All-Cause Mortality, Major Adverse Cardiovascular Events, and Major Adverse Kidney Events in Liver Transplant Recipients (ATC 2026) - "LT recipients who initiated either a GLP-1 RA or long-acting insulin (LAI; insulin glargine, detemir, or degludec) between 1/01/2007 and 11/01/2020 and who were at least one year post-transplant, were included. In this national cohort study, GLP-1RA use was associated with a lower risk of all-cause mortality, MAKE and MACE among LT recipients. GLP-1RA use was not associated with an increased risk of rejection. These findings suggest that GLP-1RAs may be a safe and effective therapeutic option for LT recipients with diabetes and/or obesity."

Adverse events • Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Genetic Disorders • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Renal Disease • Transplantation

Delayed Hypersensitivity Reaction to Insulin: A Case Report. (PubMed, Cureus) - "We report the case of a 25-year-old woman with a 2-year history of type 1 diabetes mellitus who was initially treated with insulin detemir and insulin glulisine. Insulin allergy remains a rare yet challenging condition that requires careful diagnostic evaluation. Identification of the causative mechanism, including possible hypersensitivity to excipients such as metacresol, is crucial to guide appropriate management."

Journal • Allergy • Diabetes • Immunology • Metabolic Disorders • Pain • Type 1 Diabetes Mellitus

Using NPH, Glargine, Detemir, and Other Older Insulins in Pregnancy (ADA 2026) - No abstract available

Metabolic Disorders

Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials. (PubMed, Diabetes Obes Metab) - "In T1DM, once-weekly basal insulins appear broadly comparable in reducing HbA1c at week 52. Although icodec showed a higher overall hypoglycemia risk, evidence suggests a comparable risk of severe hypoglycemias between treatments."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Structure and Dynamics of a Long-Acting Insulin Analog in Hexameric and Dihexameric States. (PubMed, bioRxiv) - "Here, we present two distinct X-ray crystallographic structures of the long-acting human insulin analog detemir (INSD) resolved in hexameric and dodecameric (or dihexameric) states at 2.85 Å and 2.70 Å resolution, respectively, using diffraction data collected under ambient temperature conditions...We distinguish in particular residues serving as hinge sites that mediates the conformational dynamics of the asymmetric units (dimers) and monomers (I2 A -V3 A and Y19 A -C20 A, and L11 B -L15 B and Y26 B of the respective peptides A and B), or as anchors supporting structural stability (disulfide-bridge forming cysteines, plus selected residues such as L16 A, G8 B and R22 B -F24 B . Overall, this study provides a structural-dynamic framework for gaining new insights into the dynamics of long-acting analog INSD and helps identify actionable sites for modulating insulin (analogs) dynamics toward designing more effective therapeutics."

Journal

Efficacy and Safety of Intranasal Insulin Therapy in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Eligible studies were RCTs comparing intranasal insulin (regular insulin, detemir, glulisine) to placebo in participants with MCI or AD. Conclusions Intranasal insulin demonstrates a modest but significant short-term benefit in individuals with MCI and early AD, without increasing AEs. While promising, the variability in formulations, sample sizes, and limited long-term data warrants the need for larger RCTs."

Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

The hidden link between diabetes and dementia: Findings from recent epidemiological studies. (PubMed, Biomed J) - "In a Taiwanese cohort study acarbose is also associated with a lower risk of dementia in female diabetes patients. When considering the repurposing of antidiabetic drugs in the treatment of patients with Alzheimer's disease, low-dose insulin detemir shows a promising effect in a network meta-analysis...Sex hormones play some roles in cognitive function and females present a higher risk of dementia than males. However, additional studies are required to explore the impacts of sex and sex hormones on the development of dementia and Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Diabetes • Hypoglycemia • Metabolic Disorders

A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues. (PubMed, Front Endocrinol (Lausanne)) - "Insulin glargine demonstrated stronger disproportionality signals for glaucoma, while degludec and detemir were more closely associated with retinopathy. These characteristics suggest the necessity of implementing individualized ophthalmic monitoring during the early phase of initiating basal insulin therapy in diabetic patients."

Adverse events • Journal • Retrospective data • Diabetes • Diabetic Retinopathy • Glaucoma • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

DUAL PANCREAS-KIDNEY TRANSPLANTATION AS A STRATEGY TO REDUCE KIDNEY TRANSPLANT WAITING TIME: A CASE REPORT FROM A PRE-TRANSPLANT EVALUATION CLINIC (ISN-WCN 2026) - "He had been diagnosed 22 years earlier, became insulin-dependent with a current insulin regimen of levemir Insulin 62 units every evening and aspart insulin 10-15 units (72-78 units of insulin per day); HbA1c 10.4%), and ultimately developed ESRD, requiring peritoneal dialysis for 3 years.During pre-transplant workup, non-invasive stress testing was normal, but coronary angiography revealed double-vessel disease...By shortening waiting time, improving donor kidney quality, and supporting superior long-term survival, SPK may represent the preferred option in selected patients. Careful patient selection and awareness of regional practice patterns remain essential to maximising these benefits."

Case report • Clinical • Pre-transplantation • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Transplantation • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=154 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

NN1436-7727: A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 Diabetes (clinicaltrialsregister.eu) - P4 | N=204 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P4 trial • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=255 | Active, not recruiting | Sponsor: Emory University | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders

How to manage patients with diabetes suffering from unstable blood glucose control due to insulin antibodies. (PubMed, Endocrine) - "We established and validated a non-isotopic method to identify suitable insulin preparations that bound less to insulin antibodies. Correcting respiratory acidosis during sleep might be effective to prevent nocturnal hypoglycemia in some patients with diabetes having insulin antibodies."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of exogenous detemir and glargine insulin on the detection of endogenous C-peptide and endogenous insulin. (PubMed, Eur J Med Res) - "Exclusive dependence on C-peptide levels as a primary metric for the direct evaluation of pancreatic function under insulin therapy is insufficient. A comprehensive assessment necessitates due consideration of the insulin type employed for quantifying insulin and C-peptide concentrations."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Insulins for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) - P=N/A | N=240 | Active, not recruiting | Sponsor: Vanderbilt University | Trial completion date: Dec 2025 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2028

Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Experience with insulin detemir for type 2 diabetes in older people and people with comorbidities. (PubMed, Diabetes Metab Syndr) - "Detemir appears to be an effective and well-tolerated treatment for T2D in older people, and those with CVD, renal disease or liver disease."

Journal • Cardiovascular • Diabetes • Hepatology • Hypoglycemia • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Early vs. late initiation of long-acting basal insulin during IV insulin in pediatric diabetic ketoacidosis: a GRADE-assessed systematic review and meta-analysis. (PubMed, Eur J Pediatr) - " In pediatric DKA, starting long-acting basal insulin during IV insulin administration with an overlap of four hours or more speeds up metabolic resolution by about 3 to 5 h without raising the risk of hypoglycemia or hypokalemia. The effects on the duration of IV insulin and LOS are inconsistent. These findings support the use of early basal insulin as a safe transition strategy. Further multicenter pragmatic RCTs with standardized definitions for overlap are needed."

Clinical • Journal • Retrospective data • Review • Hypoglycemia • Metabolic Disorders • Pediatrics

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Long-term antiepileptic therapy is often not required in dogs with insulin-induced hypoglycemic seizures: a multicenter retrospective study of 49 dogs. (PubMed, J Am Vet Med Assoc) - "Future studies are warranted to better identify patients at increased risk for long-term neurologic complications and to establish criteria for initiating AEDs. Additionally, research evaluating IIHS associated with other insulin preparations (eg, detemir, glargine) is needed."

Journal • Retrospective data • CNS Disorders • Epilepsy • Hypoglycemia